Literature DB >> 10354307

Renal proximal tubular cell fibronectin accumulation in response to glucose is polyol pathway dependent

.   

Abstract

Thickening and reduplication of the tubular basement membrane has been reported as an early event in diabetic nephropathy. In the current study we have examined the polar requirements of proximal tubular cells for the D-glucose stimulated accumulation of fibronectin. We also examined the mechanism by which glucose led to accumulation of fibronectin, with particular emphasis on the polyol pathway. Incubation of confluent monolayers of LLC-PK1 cells grown on tissue culture inserts with 25 mM D-glucose on either their apical or basolateral aspect, led to fibronectin accumulation in the basolateral compartment. This reached statistical significance 24 h following apical addition of glucose (2.7 fold increase compared to 5 mM D-glucose, p = 0.007, n = 6), and 12 h after the basolateral addition of glucose (2.54 fold increase compared to 5 mM D-glucose, p = 0.02, n = 6). The increase in fibronectin concentration in response to glucose was inhibited by the aldose reductase inhibitor sorbinil. At a dose of 100&mgr;M sorbinil there was 59% inhibition of fibronectin accumulation in response to glucose, 48 h after the addition of the inhibitor (4.76 +/- 1.4 vs 11.53 +/- 1.41, mean +/- SD, p = 0.01, n = 3). Exposure of cells to glucose at either their apical or basolateral aspect lead to accumulation of intracellular glucose and polyol pathway activation, as assessed by sorbitol accumulation. Accumulation of intracellular glucose and hence subsequent polyol pathway activation occurred independently of transport of glucose by either apical sodium linked glucose transporter (SLGT) or basolateral GLUT 1. The data demonstrate that fibronectin generation in response to glucose was non-polar in terms application of glucose, but polar in terms of fibronectin accumulation. Furthermore modulation of fibronectin was mediated by polyol pathway activation, and more specifically related to the metabolism of sorbitol to fructose.

Entities:  

Year:  1999        PMID: 10354307     DOI: 10.1046/j.1523-1755.2002.t01-1-00454.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

Review 1.  Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

Authors:  Linda A Gallo; Ernest M Wright; Volker Vallon
Journal:  Diab Vasc Dis Res       Date:  2015-01-23       Impact factor: 3.291

2.  Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy.

Authors:  Vjera Ninčević; Milorad Zjalić; Tea Omanović Kolarić; Martina Smolić; Tomislav Kizivat; Lucija Kuna; Aleksandar Včev; Ashraf Tabll; Ines Bilić Ćurčić
Journal:  Curr Issues Mol Biol       Date:  2022-02-25       Impact factor: 2.976

3.  Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.

Authors:  Hanna Shevalye; Roman Stavniichuk; Weizheng Xu; Jie Zhang; Sergey Lupachyk; Yury Maksimchyk; Viktor R Drel; Elizabeth Z Floyd; Barbara Slusher; Irina G Obrosova
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

4.  Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury.

Authors:  Yoon-Kyung Chang; Hyunsu Choi; Jin Young Jeong; Ki-Ryang Na; Kang Wook Lee; Beom Jin Lim; Dae Eun Choi
Journal:  PLoS One       Date:  2016-07-08       Impact factor: 3.240

5.  Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice.

Authors:  Linda A Gallo; Micheal S Ward; Amelia K Fotheringham; Aowen Zhuang; Danielle J Borg; Nicole B Flemming; Ben M Harvie; Toni L Kinneally; Shang-Ming Yeh; Domenica A McCarthy; Hermann Koepsell; Volker Vallon; Carol Pollock; Usha Panchapakesan; Josephine M Forbes
Journal:  Sci Rep       Date:  2016-05-26       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.